# Apoquel Oclacitinib Daily Dose: Itch Relief Dosing Chart for Dogs ## Key Takeaways - Oclacitinib (Apoquel) is a selective Janus kinase (JAK) 1 inhibitor approved for controlling pruritus associated with allergic dermatitis and clinical signs of atopic dermatitis in dogs aged 12 months or older. - The standard labeled dosing protocol involves an induction phase of 0.4-0.6 mg/kg orally twice daily for 14 days, followed by a maintenance phase of 0.4-0.6 mg/kg once daily, though some dogs require prolonged twice-daily dosing under veterinary supervision. - Prior to initiating oclacitinib, a thorough veterinary diagnosis is critical to rule out other causes of pruritus such as parasitic infestations (e.g., flea allergy dermatitis), bacterial or fungal infections, and food allergies, which require specific treatments. - Oclacitinib's mechanism involves blocking the signaling of key cytokines like IL-31, a major mediator of itch, by inhibiting JAK1, thereby interrupting the itch signal at the cellular level without broad immunosuppression. - Common adverse events include pyoderma, gastrointestinal signs (vomiting, diarrhea), and otitis externa, and while mild decreases in leukocyte counts have been observed, they typically remain within normal reference ranges. - Adjunctive therapies such as polyunsaturated fatty acid supplementation have shown potential to reduce the required oclacitinib dose, while short-course prednisolone may prevent pruritus rebound during the transition to maintenance dosing. --- **Direct answer:** The labeled induction dose of Apoquel (oclacitinib maleate) for dogs is 0.4 to 0.6 mg per kilogram of body weight, given orally twice daily for 14 days. After this induction period, the maintenance dose is the same mg/kg range given once daily for itch control. Some dogs require a prolonged twice-daily regimen or adjunctive therapy to maintain comfort, but any deviation from the label should be made under veterinary supervision. This article provides a source-grounded dosing chart, explains how oclacitinib works, reviews the evidence for standard and extended dosing, and outlines safety monitoring. It is written for veterinary professionals and for pet owners who want a deeper understanding of this medication. **Owner triage summary:** If your [dog](/knowledge/veterinary-medicine/clinical-methods/dog) is scratching, licking, or biting excessively, do not start Apoquel without a veterinary diagnosis. Itch can be caused by parasites, infections, or allergies. Apoquel controls itch but does not treat infections or parasites. Contact your veterinarian to confirm the cause and get an accurate weight-based dose. If your dog is already on Apoquel and showing signs of vomiting, diarrhea, lethargy, or new skin lesions, stop the medication and call your veterinarian. > **Veterinary disclaimer:** This article is educational and is not a substitute for veterinary diagnosis or treatment. ## At a Glance: Apoquel Dosing Chart for Dogs The table below summarizes the standard dosing protocol. Always confirm the exact tablet strength and dose with your veterinarian. | Phase | Dose (mg/kg) | Frequency | Duration | Notes | | :--- | :--- | :--- | :--- | :--- | | **Induction** | 0.4 to 0.6 | Every 12 hours (twice daily) | 14 days | Rapid itch relief often seen within hours [1] | | **Maintenance** | 0.4 to 0.6 | Every 24 hours (once daily) | Long-term, as needed | Some dogs need twice-daily dosing long-term [2] | | **Extended Twice-Daily** | 0.4 to 0.6 | Every 12 hours (twice daily) | Beyond 14 days, under veterinary supervision | Used when once-daily control is insufficient [2] | | **Chewable Tablet** | 0.4 to 0.6 | Same as above | Same as above | High palatability, accepted voluntarily in most dogs [3] | **Key clinical points from the source literature:** - **Rapid onset:** Oclacitinib reduced pruritus by 61% as early as 1.5 hours after a single oral dose in a placebo-controlled model of flea allergy dermatitis [1]. - **Efficacy in atopic dermatitis:** In a randomized trial, oclacitinib at 0.5 mg/kg twice daily significantly improved itching and skin lesions over 14 days [4]. - **Extended use:** A retrospective study of 53 dogs found that prolonged twice-daily administration (median 113 days) was effective in 72% of cases, including 24 of 33 dogs that failed once-daily therapy [2]. - **Palatability:** In a field study of 121 dogs, 91.6% of 1,673 chewable tablet doses were accepted voluntarily within 5 minutes [3]. ## Understanding Oclacitinib (Apoquel) Oclacitinib is a selective Janus kinase (JAK) 1 inhibitor. It works by blocking the signaling of several cytokines involved in allergy, inflammation, and pruritus, including IL-2, IL-4, IL-6, IL-13, and IL-31 [1]. IL-31 is particularly important because it is a major mediator of itch in allergic skin disease. By inhibiting JAK1, oclacitinib reduces the itch signal at the cellular level rather than just suppressing the immune system broadly. This mechanism is distinct from corticosteroids or cyclosporine, which have broader immunosuppressive effects. Oclacitinib is approved for the control of pruritus associated with allergic dermatitis and the control of clinical manifestations of [atopic dermatitis in dogs](/knowledge/veterinary-medicine/clinical-methods/canine-atopic-dermatitis-diagnosis-multimodal-management) at least 12 months of age [1]. ## Causes and Differentials for Pruritus in Dogs Before prescribing Apoquel, a veterinarian must rule out other causes of itching. The primary differentials include: - **Parasitic dermatitis:** Flea allergy dermatitis is a common cause. In one study, oclacitinib significantly reduced pruritus, erythema, and skin lesions in a flea allergy model [1]. - **Bacterial and fungal infections:** Pyoderma and Malassezia dermatitis can cause significant itch. These require antimicrobial or antifungal therapy, not just antipruritic treatment. - **Food allergy:** Dietary hypersensitivity can mimic atopic dermatitis. Diagnosis requires a strict elimination diet trial. - **Atopic dermatitis (environmental allergy):** This is a chronic, inflammatory skin disease. It is the primary label indication for Apoquel [2][1]. - **Autoimmune skin disease:** Conditions like autoimmune subepidermal blistering dermatosis may present with ulcers and blisters. In one case report, oclacitinib was used successfully as a steroid-sparing agent [5]. - **Cutaneous lymphoma:** Rare conditions like Sézary syndrome can cause severe pruritus and skin lesions. Oclacitinib has been explored as a palliative option in such cases [6]. **Regional considerations:** Flea control strategies vary by region. In North America and Europe, year-round flea prevention is often recommended. In Australia, flea control is a year-round necessity in many areas. Always discuss local parasite risks with your veterinarian. ## Veterinary Examination and Diagnostics A thorough workup is essential before starting Apoquel. The diagnostic plan typically includes: 1. **History and physical examination:** Assess the distribution and severity of lesions. 2. **Skin cytology:** To rule out bacterial or yeast overgrowth. 3. **Flea combing and parasite control trials:** To rule out ectoparasites. 4. **Allergy testing:** Intradermal testing (IDT) or allergen-specific IgE serology. Importantly, oclacitinib does not interfere with intradermal testing, unlike prednisolone. This means dogs can continue oclacitinib while undergoing allergy testing [7]. 5. **Food elimination trial:** If food allergy is suspected. 6. **Skin biopsy:** For atypical or non-responsive cases, especially if autoimmune disease or neoplasia is suspected [6][5]. ## Evidence-Based Management: Dosing Strategies ### Standard Induction and Maintenance The standard protocol is 0.4 to 0.6 mg/kg twice daily for 14 days, followed by once-daily maintenance [2][1]. This protocol is supported by randomized controlled trials showing significant improvement in pruritus and lesion scores [4]. ### Prolonged Twice-Daily Dosing In some dogs, once-daily dosing is insufficient. A retrospective study of 53 client-owned atopic dogs evaluated prolonged twice-daily administration (median 113 days). The study found excellent-to-good efficacy in 38 dogs (72%), including 24 of 33 dogs that had failed to respond to once-daily dosing [2]. This suggests that a subset of dogs genuinely requires twice-daily dosing for long-term control. However, this approach should be used judiciously. The same study noted that eight dogs showed a poor response even with the addition of systemic glucocorticoids [2]. This highlights the need for a multimodal approach in refractory cases. ### Dose Reduction Strategies Several studies have explored ways to reduce the maintenance dose of oclacitinib: - **Fatty acid supplementation:** A 2024 study found that oral polyunsaturated fatty acids (PUFA) significantly reduced the mean daily oclacitinib dose from 0.51 mg/kg/24h to 0.19 mg/kg/24h over 16 weeks [8]. - **Probiotics:** A pilot study of Enterococcus faecium SF68 found no significant benefit in reducing oclacitinib dose compared to placebo [9]. - **Short-course prednisolone:** A randomized controlled trial found that giving prednisolone (0.5 mg/kg twice daily) for the first 4 days of oclacitinib therapy significantly reduced the risk of a pruritus rebound when the oclacitinib frequency was reduced from twice to once daily (15% vs. 45% rebound rate) [10]. ### Off-Label and Specialized Uses Oclacitinib has been used off-label for several conditions: - **Ear tip ulcerative dermatitis (ETUD):** In a retrospective case series of 25 dogs, oclacitinib at the standard dose resolved ETUD in 22 of 25 dogs within one to three months [11]. - **Autoimmune subepidermal blistering dermatosis:** A case report documented complete resolution of clinical signs after one month of oclacitinib (0.5 mg/kg twice daily), with no relapse after 12 months [5]. - **Sézary syndrome (cutaneous T-cell lymphoma):** A case report described temporary clinical improvement with both low-dose (0.7 mg/kg twice daily) and high-dose (3 mg/kg twice daily) oclacitinib. The response was temporary, but survival exceeded previously reported cases [6]. ## Safety Profile and Adverse Events Oclacitinib is generally well tolerated, but adverse events can occur. ### Common Adverse Events in Dogs In the prolonged twice-daily study, the most frequent adverse events were pyoderma, gastrointestinal signs (vomiting, diarrhea), and otitis externa [2]. These are often related to the underlying allergic disease or secondary infections rather than direct drug toxicity. ### Laboratory Changes Blood tests in dogs on prolonged oclacitinib showed slightly decreased leukocyte, neutrophil, eosinophil, and monocyte counts, but these remained within normal reference ranges [2]. This suggests a mild, clinically insignificant effect on white blood cell counts. ### Drug Interactions A study in beagles evaluated the concomitant use of oclacitinib and ciclosporin for three weeks. The combination was well tolerated, with the only notable finding being diarrhea in two dogs [12]. However, this is not a recommended routine combination and should only be used under specialist guidance. ### Contraindications Oclacitinib is approved for dogs at least 12 months of age [1]. It should be used with caution in dogs with a history of neoplasia, as JAK inhibition could theoretically affect immune surveillance. Always discuss your dog's full medical history with your veterinarian. ## Unsafe Home Remedies and What to Avoid Do not attempt to treat your dog's itch with human medications. Many human antihistamines and corticosteroids are unsafe or improperly dosed for dogs. Do not apply topical creams or ointments intended for humans without veterinary approval, as they may be toxic if licked. Do not adjust the Apoquel dose without veterinary guidance. Giving too much can increase the risk of adverse events, while giving too little may lead to inadequate itch control and skin damage from self-trauma. ## Prevention and Long-Term Management Apoquel is not a cure for atopic dermatitis; it is a management tool. Long-term success depends on a multimodal approach: 1. **Parasite control:** Strict flea and tick prevention is essential. 2. **Allergen avoidance:** If specific allergens are identified, avoidance is the best strategy. 3. **Skin and coat care:** Regular bathing with veterinary-approved shampoos can remove allergens and support the skin barrier. 4. **Adjunctive therapies:** As noted, PUFA supplementation can help reduce the oclacitinib dose [8]. A short course of prednisolone during induction can prevent rebound pruritus [10]. 5. **Regular veterinary rechecks:** Dose adjustments should be based on clinical response and regular assessments. ## Prognosis The prognosis for dogs with allergic dermatitis managed with oclacitinib is generally good. Most dogs achieve significant itch reduction. In the prolonged twice-daily study, 72% of dogs had excellent-to-good efficacy [2]. However, a subset of dogs (about 15-28%) may have a poor response or require additional therapies [2]. ## Limitations and When to Contact a Veterinarian This article provides general dosing information based on published studies. It cannot predict how an individual dog will respond. Breed, age, concurrent illness, and other medications can all influence the safety and efficacy of oclacitinib. **Contact your veterinarian immediately if you observe:** - Vomiting or diarrhea that persists for more than 24 hours [2]. - New or worsening skin lesions, especially pustules or crusts (possible pyoderma) [2]. - Lethargy, weakness, or collapse. - Loss of appetite lasting more than 24 hours. - Any signs of an allergic reaction (facial swelling, hives, difficulty breathing). Do not stop or change the dose of Apoquel without consulting your veterinarian. Sudden discontinuation can lead to a rebound of pruritus [10]. ## Clinical Pharmacology: How Oclacitinib Works at the Cellular Level Understanding the mechanism of oclacitinib requires a closer look at the Janus kinase (JAK) signaling pathway. When an allergen or irritant triggers an immune response, cytokines bind to receptors on cell surfaces, activating JAK enzymes. These enzymes then phosphorylate signal transducers and activators of transcription (STAT) proteins, which travel to the nucleus and initiate the transcription of genes responsible for inflammation and pruritus. Oclacitinib selectively inhibits JAK1, which is the primary JAK family member involved in mediating the effects of pruritogenic and pro-inflammatory cytokines [1]. The selectivity of oclacitinib for JAK1 over other JAK family members is a key feature of its safety profile. JAK2 is involved in erythropoietin signaling and hematopoiesis, while JAK3 is important for immune cell development. By preferentially inhibiting JAK1, oclacitinib targets the itch and inflammation pathways while minimizing effects on red blood cell production and broad immune function [1]. This selectivity distinguishes it from older, less targeted immunomodulatory drugs. Interleukin-31 (IL-31) deserves special attention in the context of canine pruritus. This cytokine is released by T-helper 2 (Th2) cells and acts directly on sensory neurons in the skin to trigger the sensation of itch. Oclacitinib's inhibition of JAK1 blocks IL-31 receptor signaling, effectively interrupting the itch signal at its source [1]. This explains the rapid onset of action observed in clinical studies, where pruritus reduction was documented within hours of a single dose [1]. The downstream effects of JAK1 inhibition extend beyond IL-31. Oclacitinib also modulates the signaling of IL-2, IL-4, IL-6, and IL-13, which are involved in the broader inflammatory cascade of allergic skin disease [1]. This multi-cytokine blockade helps explain why oclacitinib is effective not only for pruritus but also for reducing visible skin lesions such as erythema and excoriations. ## The Diagnostic Journey: From Itch to Diagnosis The diagnostic approach to a pruritic dog is systematic and often requires multiple steps. The first priority is to rule out ectoparasites, as flea allergy dermatitis is one of the most common causes of intense pruritus in dogs. In the flea allergy model study, oclacitinib significantly reduced pruritus, erythema, and skin lesions, confirming that JAK1 inhibition is effective even when the underlying trigger is parasitic rather than environmental [1]. However, this does not mean oclacitinib treats the flea infestation itself; it only controls the clinical signs. Flea control must be implemented concurrently. Skin cytology is a cornerstone of the diagnostic workup. Impression smears and tape strips can reveal bacterial cocci or Malassezia yeast organisms. If secondary infections are present, they must be treated with appropriate antimicrobial or antifungal therapy. Starting oclacitinib without addressing an active pyoderma can mask the clinical signs of infection while the infection continues to spread. This is why the owner triage summary emphasizes the importance of a veterinary diagnosis before starting any antipruritic medication. For suspected food allergy, an elimination diet trial is the gold standard for diagnosis. This involves feeding a novel protein or hydrolyzed protein diet exclusively for a minimum of 8 weeks. Oclacitinib can be used during this trial to control pruritus, but the owner must understand that the medication will not interfere with the dietary trial results. If pruritus resolves during the elimination diet and recurs upon rechallenge with the original diet, a food allergy diagnosis is confirmed. Intradermal testing (IDT) and allergen-specific IgE serology are used to identify environmental allergens for immunotherapy. A critical advantage of oclacitinib is that it does not interfere with these tests. A study in Dermatophagoides farinae-sensitized beagle dogs demonstrated that oclacitinib did not suppress the wheal-and-flare responses to intradermal injections or alter serum allergen-specific IgE levels [7]. This is in contrast to glucocorticoids, which can suppress IDT responses for weeks. For dogs already on oclacitinib, allergy testing can proceed without a washout period, saving time and reducing the risk of pruritus flare during testing [7]. Skin biopsy is reserved for atypical presentations, non-responsive cases, or when autoimmune or neoplastic disease is suspected. In the case of presumed autoimmune subepidermal blistering dermatosis, biopsy was essential for diagnosis, and oclacitinib was then used successfully as a steroid-sparing agent [5]. Similarly, in the Sézary syndrome case, skin biopsy and flow cytometry confirmed the diagnosis of cutaneous T-cell lymphoma before oclacitinib was explored as a palliative option [6]. ## Practical Dosing Considerations: Tablet Strengths and Weight Calculations Apoquel is available in multiple tablet strengths, typically including 3.6 mg, 5.4 mg, and 16 mg tablets. The chewable formulation is also available in corresponding strengths [3]. The labeled dose range of 0.4 to 0.6 mg/kg means that for a given dog weight, the veterinarian selects the tablet strength that falls within this range. For example, a 10 kg dog would require a dose between 4 mg and 6 mg per administration. The 5.4 mg tablet would be appropriate, as it falls within this range. A 20 kg dog would require 8 to 12 mg, making the 16 mg tablet too high and the 5.4 mg tablet too low, so two 5.4 mg tablets (10.8 mg total) would be appropriate. A 30 kg dog would require 12 to 18 mg, and the 16 mg tablet would be suitable. Owners should never attempt to split tablets to achieve an exact dose unless specifically instructed by their veterinarian. Tablet splitting can lead to inaccurate dosing, and some tablets are not scored for splitting. The chewable formulation is designed to be given whole, and the palatability study showed that most dogs accept the tablet voluntarily within 5 minutes [3]. This high acceptance rate reduces the stress of medication administration for both the dog and the owner. Accurate weighing is essential. A dog's weight can fluctuate, and dose adjustments may be needed over time. Owners should have their dog weighed at every veterinary visit and discuss any significant weight changes with their veterinarian. The dose should be recalculated if the dog gains or loses more than 10% of its body weight. ## The Induction Phase: What to Expect in the First Two Weeks The first 14 days of oclacitinib therapy are considered the induction phase, during which the medication is given every 12 hours. This twice-daily dosing provides more consistent drug levels to rapidly bring pruritus under control. The rapid onset of action is one of the most appreciated features of this medication. In the flea allergy model, pruritus was reduced by 61% as early as 1.5 hours after a single oral dose, with an average reduction of 85% compared to placebo over the first 1 to 5 hours after dosing [1]. Owners should expect to see noticeable improvement within the first 24 to 48 hours of induction therapy. However, complete resolution of all skin lesions may take longer. Erythema, excoriations, and self-induced alopecia will heal gradually as the itch is controlled and the skin barrier recovers. Secondary bacterial or yeast infections, if present, will require additional treatment and may take several weeks to resolve. During the induction phase, owners should monitor their dog for any adverse effects. Gastrointestinal signs such as vomiting or diarrhea are among the most commonly reported adverse events [2]. Mild and transient gastrointestinal upset can sometimes occur as the dog adjusts to the medication. If vomiting or diarrhea persists for more than 24 hours, or if the dog becomes lethargic or refuses food, the veterinarian should be contacted immediately. The induction phase is also the time when the short-course prednisolone strategy may be employed. A randomized controlled trial demonstrated that giving prednisolone at 0.5 mg/kg twice daily for the first 4 days of oclacitinib therapy significantly reduced the risk of a pruritus rebound when the oclacitinib frequency was reduced from twice to once daily [10]. The rebound rate was 15% in the prednisolone group compared to 45% in the placebo group [10]. This strategy can be particularly helpful for dogs with severe pruritus or for owners who are concerned about a flare when transitioning to maintenance dosing. ## The Maintenance Phase: Transitioning to Once-Daily Dosing After the 14-day induction period, the standard protocol is to reduce the frequency to once daily. This transition is a critical juncture in therapy. Some dogs maintain excellent itch control on once-daily dosing, while others experience a return of pruritus within a few days or weeks. The decision to transition to once-daily dosing should be based on the dog's clinical response during the induction phase. If the dog achieved complete or near-complete resolution of pruritus and skin lesions, the transition is likely to be successful. If the dog still has significant pruritus at the end of the induction phase, the veterinarian may recommend continuing twice-daily dosing for a longer period or adding adjunctive therapies. Owners should be prepared for the possibility that their dog may need a dose adjustment during the maintenance phase. It is not uncommon for dogs to require a temporary return to twice-daily dosing during allergy season or when exposed to a known allergen. The veterinarian may also recommend a trial of dose reduction to find the lowest effective dose that maintains comfort. The prolonged twice-daily study provides valuable data on dogs that do not achieve adequate control with once-daily dosing. In this retrospective study of 53 client-owned atopic dogs, prolonged twice-daily administration was used for a median of 113 days [2]. Excellent-to-good efficacy was achieved in 38 dogs (72%), including 24 of 33 dogs that had failed to respond to once-daily dosing [2]. This suggests that a significant subset of dogs genuinely requires twice-daily dosing for long-term control. However, the study also highlighted the limitations of this approach. Eight dogs showed a poor response even with the addition of systemic glucocorticoids [2]. This underscores the need for a multimodal approach in refractory cases and the importance of identifying and addressing all contributing factors, including secondary infections, flea allergy, and food allergy. ## Adjunctive Therapies: Reducing the Oclacitinib Dose The concept of using adjunctive therapies to reduce the required oclacitinib dose is appealing for several reasons. Lower doses may reduce the risk of adverse events, lower the cost of long-term therapy, and minimize any theoretical concerns about chronic JAK inhibition. ### Polyunsaturated Fatty Acids (PUFAs) A 2024 placebo-controlled, double-blind study evaluated the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose in atopic dogs [8]. The study found that PUFA supplementation significantly reduced the mean daily oclacitinib dose from 0.51 mg/kg/24h to 0.19 mg/kg/24h over 16 weeks [8]. This represents a substantial dose reduction, suggesting that PUFAs have a genuine steroid-sparing or oclacitinib-sparing effect. The mechanism by which PUFAs exert this effect is not fully understood but may involve modulation of the inflammatory response and improvement of the skin barrier. Omega-3 and omega-6 fatty acids are incorporated into cell membranes and can influence the production of pro-inflammatory and anti-inflammatory mediators. For owners, this means that adding a veterinary-recommended fatty acid supplement may allow their dog to achieve the same level of itch control with a lower oclacitinib dose. It is important to note that not all fatty acid supplements are created equal. The dose and ratio of omega-3 to omega-6 fatty acids matter, and owners should use a product recommended by their veterinarian. The study used a specific formulation, and the results may not be generalizable to all over-the-counter supplements [8]. ### Probiotics A pilot study evaluated the use of Enterococcus faecium SF68 as an adjunctive therapy for oclacitinib-responsive atopic dermatitis in dogs [9]. Unlike the PUFA study, this pilot study found no significant benefit in reducing the oclacitinib dose compared to placebo [9]. This highlights the importance of evidence-based adjunctive therapies. While probiotics may have other health benefits, they should not be relied upon as a strategy to reduce oclacitinib requirements. ### Short-Course Prednisolone The use of a short course of prednisolone during the induction phase has already been discussed. This strategy is not intended to reduce the maintenance oclacitinib dose but rather to prevent a pruritus rebound when transitioning from twice-daily to once-daily dosing [10]. The 4-day course of prednisolone at 0.5 mg/kg twice daily is short enough to minimize the risk of glucocorticoid-related adverse events while providing additional anti-inflammatory cover during the transition. ## Special Populations: Age, Breed, and Concurrent Disease ### Young Dogs Oclacitinib is approved for dogs at least 12 months of age [1]. This age restriction is based on the safety data available at the time of approval. For dogs under 12 months of age, the safety and efficacy of oclacitinib have not been established, and alternative therapies may be considered. Young dogs with allergic dermatitis can be challenging to manage, and the veterinarian will weigh the risks and benefits of all available options. ### Senior Dogs Older dogs may have concurrent diseases such as chronic kidney disease, liver disease, or heart disease that could influence the safety of oclacitinib. While oclacitinib is generally well tolerated, a thorough pre-treatment evaluation, including blood work and urinalysis, is recommended for senior dogs. The veterinarian may also recommend more frequent monitoring during long-term therapy. ### Dogs with a History of Neoplasia The theoretical concern about JAK inhibition and immune surveillance means that oclacitinib should be used with caution in dogs with a history of cancer. However, the case report of Sézary syndrome demonstrated that oclacitinib can be used in dogs with confirmed neoplasia, albeit with the expectation of only temporary clinical improvement [6]. The decision to use oclacitinib in a dog with a history of cancer should be made on a case-by-case basis, considering the severity of the pruritus and the availability of alternative therapies. ### Breed Predispositions Certain breeds are predisposed to atopic dermatitis, including West Highland White Terriers, French Bulldogs, Golden Retrievers, Labrador Retrievers, and German Shepherd Dogs. While oclacitinib is effective across breeds, the underlying genetic predisposition means that long-term management is often necessary. Owners of predisposed breeds should be prepared for the possibility of lifelong therapy and should work closely with their veterinarian to optimize the treatment plan. ## Monitoring and Long-Term Safety Long-term safety monitoring is an essential component of oclacitinib therapy. The retrospective study of prolonged twice-daily administration provided valuable data on the safety profile of extended dosing [2]. The most frequent adverse events were pyoderma, gastrointestinal signs (vomiting, diarrhea), and otitis externa [2]. These are often related to the underlying allergic disease or secondary infections rather than direct drug toxicity. Blood tests in dogs on prolonged oclacitinib showed slightly decreased leukocyte, neutrophil, eosinophil, and monocyte counts, but these remained within normal reference ranges [2]. This suggests a mild, clinically insignificant effect on white blood cell counts. However, this finding underscores the importance of periodic blood work in dogs on long-term therapy, particularly if the dog develops signs of illness. The recommended monitoring schedule may vary depending on the individual dog and the duration of therapy. A reasonable approach includes a complete blood count and serum biochemistry profile every 6 to 12 months for dogs on continuous therapy. More frequent monitoring may be recommended for senior dogs or dogs with concurrent disease. Owners should also be vigilant for signs of secondary infections. Pyoderma can develop even when pruritus is well controlled, as the underlying skin barrier dysfunction persists. New pustules, crusts, or circular areas of hair loss should prompt a veterinary examination. Similarly, otitis externa is common in atopic dogs, and owners should check their dog's ears regularly for redness, discharge, or odor. ## Drug Interactions and Combination Therapy The potential for drug interactions is an important consideration in any chronic therapy. A study in beagles evaluated the concomitant use of oclacitinib and ciclosporin for three weeks [12]. The combination was well tolerated, with the only notable finding being diarrhea in two dogs [12]. However, this is not a recommended routine combination and should only be used under specialist guidance. Both drugs have immunomodulatory effects, and the long-term safety of concurrent use has not been established. The combination of oclacitinib with glucocorticoids is more common, particularly during the induction phase. The short-course prednisolone strategy has been shown to be beneficial in preventing rebound pruritus [10]. However, long-term concurrent use of oclacitinib and glucocorticoids should be avoided due to the additive immunosuppressive effects and the risk of glucocorticoid-related adverse events. Oclacitinib can be used concurrently with antihistamines, though the evidence for additional benefit is limited. Some veterinarians may recommend an antihistamine for dogs that have breakthrough pruritus between oclacitinib doses. The decision to add an antihistamine should be made by the veterinarian, as not all antihistamines are safe or effective in dogs. ## Owner Education: Administering Apoquel Correctly Proper administration of Apoquel is essential for therapeutic success. The chewable formulation has been shown to be highly palatable, with 91.6% of 1,673 total dose administrations accepted voluntarily within 5 minutes [3]. This high acceptance rate means that most dogs will take the medication without a struggle, reducing stress for both the dog and the owner. For dogs that are reluctant to take the chewable tablet, it can be hidden in a small amount of food. However, owners should avoid mixing the tablet into a full meal, as this can make it difficult to ensure the dog consumes the entire dose. A small treat or a spoonful of peanut butter (xylitol-free) is often sufficient. Apoquel can be given with or without food. If the dog experiences gastrointestinal upset, giving the medication with a small amount of food may help. The tablet should be given at approximately the same time each day to maintain consistent drug levels. If a dose is missed, the owner should give the next dose as soon as they remember, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the normal schedule should be resumed. A double dose should never be given to make up for a missed dose. ## The Role of Allergen-Specific Immunotherapy Allergen-specific immunotherapy (ASIT), also known as allergy shots or sublingual immunotherapy, is the only disease-modifying treatment for atopic dermatitis. Unlike oclacitinib, which controls clinical signs, ASIT aims to desensitize the immune system to specific allergens over time. ASIT can be used concurrently with oclacitinib, and the lack of interference with allergy testing is a significant advantage [7]. For dogs that respond well to ASIT, the oclacitinib dose may be gradually reduced over time. Some dogs may eventually be able to discontinue oclacitinib entirely or use it only during peak allergy seasons. However, ASIT is a long-term commitment, and it can take 6 to 12 months to see significant improvement. The decision to pursue ASIT should be made in consultation with a veterinary dermatologist. Intradermal testing or allergen-specific IgE serology is required to identify the relevant allergens, and the immunotherapy formulation is customized for each dog. While ASIT does not work for every dog, it offers the potential for long-term reduction in medication requirements. ## Prognosis and Quality of Life The prognosis for dogs with allergic dermatitis managed with oclacitinib is generally good. Most dogs achieve significant itch reduction, and the rapid onset of action is a major advantage. In the prolonged twice-daily study, 72% of dogs had excellent-to-good efficacy [2]. This means that the majority of dogs can achieve a good quality of life with appropriate management. However, it is important to set realistic expectations. Atopic dermatitis is a chronic, relapsing condition, and there is no cure. Oclacitinib controls the clinical signs but does not address the underlying immune dysregulation. Flare-ups can occur, particularly during allergy season or when the dog is exposed to a known allergen. The subset of dogs that do not respond adequately to oclacitinib, approximately 15 to 28%, may require additional therapies [2]. These dogs may benefit from referral to a veterinary dermatologist for a comprehensive management plan. The dermatologist can perform a thorough diagnostic workup, recommend allergen-specific immunotherapy, and adjust the treatment protocol as needed. Owners should also be aware of the financial implications of long-term therapy. Oclacitinib is a prescription medication, and the cost can be significant, particularly for larger dogs or dogs that require twice-daily dosing. Owners should discuss the cost of therapy with their veterinarian and explore options such as purchasing medication from a reputable online pharmacy or using a pet insurance plan that covers prescription medications. ## When to Seek Emergency Care While oclacitinib is generally well tolerated, owners should be aware of the signs that warrant immediate veterinary attention. Persistent vomiting or diarrhea lasting more than 24 hours can lead to dehydration and electrolyte imbalances [2]. New or worsening skin lesions, especially pustules or crusts, may indicate a secondary bacterial infection that requires antimicrobial therapy [2]. Lethargy, weakness, or collapse are nonspecific signs that warrant prompt evaluation. Loss of appetite lasting more than 24 hours can be a sign of an underlying issue. Any signs of an allergic reaction, such as facial swelling, hives, or difficulty breathing, require immediate emergency care. Owners should never stop or change the dose of oclacitinib without consulting their veterinarian. Sudden discontinuation can lead to a rebound of pruritus [10]. If a dog is doing well on a particular dose, the veterinarian may recommend continuing that dose indefinitely, with periodic rechecks to assess the ongoing need for therapy. ## The Future of JAK Inhibition in Veterinary Dermatology The success of oclacitinib has paved the way for the development of other JAK inhibitors for veterinary use. The pharmacokinetic and pharmacodynamic study of IN-115314, a novel small molecule JAK-STAT inhibitor, represents an ongoing area of research [13]. This compound has demonstrated JAK-STAT inhibitory effects and is being studied in canine models [13]. The development of new JAK inhibitors may offer additional options for dogs that do not respond adequately to oclacitinib or for those that experience adverse events. However, oclacitinib remains the most extensively studied JAK inhibitor in veterinary dermatology, with a well-established safety and efficacy profile. The off-label use of oclacitinib in cats is also an area of active investigation. Several studies have evaluated oclacitinib for the control of feline allergic pruritus [14][15][16][17]. While oclacitinib is not approved for use in cats, these studies have shown variable efficacy, and the drug is sometimes used off-label in feline patients under specialist guidance. The retrospective case series of 238 cats reported on the clinical efficacy and adverse events of oclacitinib administration for skin disease in cats [14]. A small prospective pilot study evaluated oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis [16], and another study correlated plasma concentrations with clinical response in cats with atopic skin syndrome [17]. These feline studies are important because they expand the potential applications of oclacitinib beyond canine patients. However, the use of oclacitinib in cats should only be considered when other therapies have failed, and it should be closely monitored by a veterinarian familiar with feline dermatology. ## Preparing for the Veterinary Visit Owners can maximize the value of their veterinary visit by being prepared. Before the appointment, the owner should note the onset and duration of the itching, the distribution of lesions on the dog's body, and any factors that seem to worsen or improve the itching. A video of the dog scratching can be helpful, as some dogs do not exhibit the behavior in the examination room. The owner should also bring a list of all medications and supplements the dog is currently receiving, including over-the-counter products. This information is essential for assessing potential drug interactions. A complete dietary history, including treats and table scraps, is also important, particularly if food allergy is suspected. During the examination, the veterinarian will likely ask about the dog's environment, including exposure to other animals, recent changes in the household, and the use of flea and tick prevention. The owner should be prepared to answer these questions honestly and completely. After the examination, the owner should ask about the expected timeline for improvement, the potential adverse events to watch for, and the plan for follow-up. It is also reasonable to ask about the cost of therapy and whether there are any generic or alternative options available. ## Summary of Key Owner Takeaways The management of canine allergic dermatitis with oclacitinib is a partnership between the owner and the veterinarian. The owner's role is to administer the medication correctly, monitor the dog for adverse events, and report any concerns promptly. The veterinarian's role is to make an accurate diagnosis, calculate the appropriate dose, and adjust the treatment plan based on the dog's response. The labeled dose of 0.4 to 0.6 mg/kg twice daily for 14 days, followed by once-daily maintenance, is the foundation of therapy [2][1]. Some dogs require prolonged twice-daily dosing, and this should be done under veterinary supervision [2]. Adjunctive therapies such as PUFA supplementation can reduce the oclacitinib dose [8], while a short course of prednisolone can prevent rebound pruritus during the transition to maintenance dosing [10]. Oclacitinib does not interfere with allergy testing, which is a significant advantage for dogs that require intradermal testing or allergen-specific IgE serology [7]. This allows the diagnostic workup to proceed without a medication washout period. The prognosis for most dogs is good, with 72% achieving excellent-to-good efficacy in the prolonged twice-daily study [2]. However, atopic dermatitis is a chronic condition that requires long-term management. Regular veterinary rechecks, periodic blood work, and a multimodal approach that includes parasite control, skin care, and adjunctive therapies are essential for optimal outcomes. Owners should never adjust the oclacitinib dose without veterinary guidance, and they should contact their veterinarian immediately if they observe persistent vomiting or diarrhea, new skin lesions, lethargy, loss of appetite, or any signs of an allergic reaction [2]. With appropriate management, most dogs with allergic dermatitis can achieve a good quality of life and maintain comfort for years. ## Frequently Asked Questions ### How fast does Apoquel start working for itching in dogs? Apoquel can start working very quickly. In a controlled study, oclacitinib reduced pruritus by 61% as early as 1.5 hours after a single oral dose, with an average reduction of 85% compared to placebo over the first 1 to 5 hours after dosing [1]. ### What is the exact Apoquel dose for my dog's weight? The dose is 0.4 to 0.6 mg per kilogram of body weight, given twice daily for 14 days, then once daily for maintenance. You must weigh your dog accurately and use the appropriate tablet strength. Do not guess the dose; ask your veterinarian to calculate it. ### Can I give my dog Apoquel twice a day for longer than 14 days? Yes, in some cases. A retrospective study of 53 dogs found that prolonged twice-daily administration (median 113 days) was effective in 72% of cases, especially in dogs that did not respond well to once-daily dosing. This should only be done under veterinary supervision [2]. ### Is Apoquel safe for long-term use in dogs? Yes, for most dogs. The most common adverse events in long-term studies were pyoderma, gastrointestinal signs, and otitis externa, which are often related to the underlying allergic disease. Blood tests showed only mild, clinically insignificant changes in white blood cell counts [2]. ### Can I give Apoquel with other allergy medications? Sometimes, but only under veterinary guidance. One study showed that a short 4-day course of prednisolone at the start of Apoquel therapy reduced the risk of a pruritus rebound [10]. Another study showed that Apoquel and ciclosporin can be given together for three weeks, but this combination is not routinely recommended [12]. ### Does Apoquel interfere with allergy testing for my dog? No. A study in sensitized beagle dogs showed that oclacitinib did not interfere with intradermal testing (IDT) or allergen-specific IgE serology, unlike prednisolone. This means your dog can continue Apoquel while undergoing allergy testing [7]. ### What should I do if my dog misses a dose of Apoquel? If you miss a dose, give the next dose as soon as you remember, unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the normal schedule. Do not give a double dose. Contact your veterinarian if you have any concerns. ### Are there chewable Apoquel tablets that are easier to give? Yes. A 2022 study evaluated oclacitinib chewable tablets and found them to be very palatable. Out of 1,673 total dose administrations, 91.6% were accepted voluntarily within 5 minutes, with no aversion occurring with repeated dosing [3]. ## Sources [1] [Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis.](https://pubmed.ncbi.nlm.nih.gov/38926932/) [2] [Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs.](https://pubmed.ncbi.nlm.nih.gov/35014745/) [3] [Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis.](https://pubmed.ncbi.nlm.nih.gov/35300697/) [4] [A randomized double-blind clinical trial: Comparison of oclacitinib with a traditional Chinese herbal medicine product (Dihuang Guiqin capsule) in the treatment of canine atopic dermatitis.](https://pubmed.ncbi.nlm.nih.gov/38490043/) [5] [A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib.](https://pubmed.ncbi.nlm.nih.gov/28635010/) [6] [Case Report: Dose-dependent response to oclacitinib in a dog with Sézary syndrome.](https://pubmed.ncbi.nlm.nih.gov/41473101/) [7] [Lack of Interference of Oclacitinib with the results of intradermal testing or allergen-specific IgE serology in Dermatophagoides farinae-sensitized beagle dogs.](https://pubmed.ncbi.nlm.nih.gov/36603446/) [8] [A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs.](https://pubmed.ncbi.nlm.nih.gov/38465482/) [9] [Pilot evaluation of Enterococcus faecium SF68 as adjunctive therapy for oclacitinib-responsive adult atopic dermatitis in dogs.](https://pubmed.ncbi.nlm.nih.gov/31257599/) [10] [A randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis.](https://pubmed.ncbi.nlm.nih.gov/36330780/) [11] [Ear tip ulcerative dermatitis treated with oclacitinib in 25 dogs: a retrospective case series.](https://pubmed.ncbi.nlm.nih.gov/34250688/) [12] [Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.](https://pubmed.ncbi.nlm.nih.gov/26660461/) [13] [JAK-STAT inhibitory effect of IN-115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine.](https://pubmed.ncbi.nlm.nih.gov/40341986/) [14] [A Retrospective Case Series Reporting the Clinical Efficacy and Adverse Events of Oclacitinib Administration for Skin Disease in 238 Cats.](https://pubmed.ncbi.nlm.nih.gov/42036967/) [15] [Long-term oclacitinib administration for the control of feline allergic pruritus: A retrospective study of 14 client-owned cats.](https://pubmed.ncbi.nlm.nih.gov/40786738/) [16] [Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats.](https://pubmed.ncbi.nlm.nih.gov/25940959/) [17] [Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response.](https://pubmed.ncbi.nlm.nih.gov/34612749/) ## Related Clinical & Scientific Guides * [Drontal Plus Dewormer: Broad-Spectrum Dose Guide by Weight](/knowledge/veterinary-medicine/calculators-clinical-tools/drontal-plus-dewormer-broad-spectrum-dose-guide-by-weight) * [Panacur Fenbendazole Dewormer: Dog Fecal Parasite Treatment Schedule](/knowledge/veterinary-medicine/calculators-clinical-tools/panacur-fenbendazole-dewormer-dog-fecal-parasite-treatment-schedule) * [Prednisolone for Cats: Feline Safe Steroid Dose and Autoimmune](/knowledge/veterinary-medicine/calculators-clinical-tools/prednisolone-for-cats-feline-safe-steroid-dose-and-autoimmune)